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Inhibition of PLCγ enzymatic activity blocks OC differentiation and dis-














































PLCγ inhibition blocks osteoclastogenesis and actin ring 
formation. (A) WT OCs were generated with RANKL (100 
ng/ml) and M-CSF (10 ng/ml) in the presence of the PLC 
inhibitor U73122 (5 μM) for 4 days on plastic. In some wells, 
the media with the inhibitor was replaced with fresh osteo-
clastogenic media, and cells were allowed to differentiate 
for 4 more days (Withdrawal U73122). (B) WT OCs were 
grown on dentin with or without U73122 for 10 days. Cells 
were then removed and pits stained with hematoxylin red 
(Magnification, ×200). CTR, control. (C) WT OCs were gen-
erated on dentin in the absence of the inhibitor, then treated 
with vehicle or U73122 for 1 hour. Cells were fixed and actin 
stained using FITC-phalloidin (Magnification, ×200).
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PLCγ2 is required for efficient RANKL-induced activation of AP1 and 






















Osteopetrosis in mice lacking PLCγ2. (A) 
TRAP staining of decalcified histological sec-
tions of WT and Plcg2–/– proximal femurs. 
Magnification, ×40. (B–E) Quantitative analy-
sis of bone parameters from histological sec-
tions of WT and Plcg2–/– bone femurs (n = 8) 
showing: percentage of bone volume versus 
total bone volume (BV/TV) (B); number of 
OBs (nOB) per bone perimeter (C); number 
of OCs (nOC) per bone perimeter (D); frac-
tion of trabecular surface covered by OCs (E). 
(F) 3D reconstitution of μCT scans of WT and 
Plcg2–/– femurs. (G–I) 3D trabecular quanti-
tative parameters of bone structure (n = 6). 
Graphs show mean ± SEM, with significant 
differences compared with WT indicated.
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PLCγ2 is phosphorylated by RANKL via Dap12-mediated costimulatory sig-
























Since  costimulatory  signals  are 


















PLCγ2 catalytic activity is required for 
NFATc1 upregulation but not for JNK and 
IκBα phosphorylation. Our data indicate 
























PLCγ2 is required for osteoclastogenesis. (A) Bone nodule formation in WT and Plcg2–/– OBs cul-
tured with ascorbic acid and β-glycerolphosphate. (B) Double labeling of calvarial bones showing the 
degree of bone formation (BFR) of WT and Plcg2–/– mice injected on day 0 and day 7 with calcein 
(WT BFR, 0.8938 ± 0.1042 μm3/μm2/d; WT mineral apposition rate [MAR], 0.5927 ± 0.0219 μm/d; 
Plcg2–/– BFR, 0.8450 ± 0.1629 μm3/μm2/d; Plcg2–/– MAR, 0.4015 ± 0.0876 μm/d). (C) WT and Plcg2–/– 
BMMs cultured with WT and Plcg2–/– OBs in the presence of 10–8 M 1,25 Vit D3. After 14 days, cells 
were fixed and TRAP stained to detect the presence of multinucleated OCs. (D) TRAP-stained OCs 
generated with RANKL (100 ng/ml) and M-CSF (10 ng/ml) for 5 days (top panel) and bone resorptive 
pits generated from OCs plated on dentin for 7 days. Pits were stained with hematoxylin red. (E) WT 
and Plcg2–/– BMMs retrovirally transduced with vector alone (pMX) or with Flag-tagged PLCγ2 were 
allowed to differentiate in osteoclastogenic media for 5 days, then stained for TRAP. Magnification, 
×200 (A, C–E); ×100 (B).
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PLCγ2 regulates NFATc1 levels and the expression of early 
osteoclastogenic genes. (A–D) Real-time PCR analysis of 
osteoclastogenic markers in WT and Plcg2–/– cells in cul-
ture with M-CSF alone (d0) or with RANKL (100 ng/ml) plus 
M-CSF (10 ng/ml) for 4 days (d4). Data are normalized rela-
tive to β-actin. ND, not detected. Significant differences com-
pared with WT are shown. (E) Expression levels of NFATc1 
protein in total cell lysates from day 4 WT and Plcg2–/– OCs, 
starved for 6 hours and stimulated with RANKL for 0, 5, 20, 
and 60 minutes. PLCγ1 and PLCγ2 levels are shown. β-Actin 
served as loading control.
Figure 5
PLCγ2 modulates RANKL-mediated sig-
naling. (A) Activation of ERK and JNK in 
WT and Plcg2–/– BMMs in response to 
M-CSF (100 ng/ml). PLCγ1 and PLCγ2 
levels are shown. (B) Western blot anal-
ysis of phospho-ERK, phospho-JNK, 
phospho–c-Jun, and phospho-IκBα in 
total cell lysates from WT and Plcg2–/– 
BMMs stimulated with RANKL (100 ng/
ml) for the indicated times. β-Actin blots 
served as loading control for A and B. 
(C) Nuclear levels of phospho–c-Jun 
and p65 in nuclear extracts from WT and 
Plcg2–/– BMMs stimulated with RANKL. 
(D) The same samples used in C were 
subjected to AP1 and NF-κB nonradio-
active EMSA analysis. To control for 
binding specificity, a concentration of 
unlabeled oligonucleotides (U.O.) 200-
fold greater than that recommended by 
the manufacturer was added to nuclear 
extracts from WT cells stimulated with 
RANKL for 60 minutes. SP1 served as 
loading control for C and D.
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PLCγ2 is activated by RANKL via Dap12/FcRγ in an SFK-dependent manner. (A) WT OC precursors (preOCs; BMMs grown in RANKL-contain-
ing media for 2 days) cultured with the SFK inhibitor PP2 (5 μM) or vehicle (DMSO) were stimulated with RANKL and subjected to Western blot 
analysis to detect phosphorylated levels of PLCγ2, Src, and NFATc1. β-Actin served as control. (B) PLCγ1 and PLCγ2 phosphorylation in response 
to RANKL were measured by Western blot analysis in WT and Plcg2–/– preOCs. PLCγ1 and PLCγ2 levels are shown. (C) PLCγ1 and PLCγ2 phos-
phorylation in response to 5 minutes of treatment with either M-CSF or RANKL in WT and Plcg2–/– preOCs. β-Actin served as control. (D) Expres-
sion levels of endogenous Dap12 and Flag-tagged Dap12 retrovirally transduced in Dap12–/–FcRγ–/– BMMs are shown. ΔKO, Dap12–/–FcRγ–/–. (E) 
PLCγ2 phosphorylation was measured by Western blot analysis in WT, Dap12–/–FcRγ–/–, or Dap12–/–FcRγ–/– preOCs reconstituted with WT Dap12 
stimulated with RANKL for the indicated times. Phospho-JNK is also shown. β-Actin served as loading control. (F) Nuclear localization of NFATc1 
in WT and Dap12–/–FcRγ–/– OCs retrovirally transduced with pMX or Flag-tagged Dap12 is shown in red (left panels). Actin staining is shown in 
green, and nuclei, stained with DAPI, are shown in blue (right panels) (objective, ×20). Enlarged images (2.5-fold) show nuclear localization of 
NFATc1 (red) and nuclei stained with DAPI (blue) of representative cells located in the center of the photographed field.
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PLCγ2 forms a complex with GAB2 and modulates its activation. (A) WT preOCs cultured with or without the PLC inhibitor U73122 (5 μM) for 
3 days were stimulated with RANKL and subjected to Western blot analysis for phospho-JNK, phospho-IκBα, and NFATc1. β-Actin served as 
control. (B) WT and Plcg2–/– BMMs retrovirally transduced with empty vector (pMX), WT PLCγ2, or catalytically inactive PLCγ2 (PLCγ2 H/F) were 
cultured with RANKL (100 ng/ml) and M-CSF (10 ng/ml) for 7 days, and multinucleated OCs were detected by TRAP staining. Objective, ×10. (C) 
The same cells as shown in B were subjected to RANKL stimulation and Western blot analysis to detect NFATc1 expression. (D) Plcg2–/– BMMs 
retrovirally transduced with pMX, WT PLCγ2, or PLCγ2 H/F were treated with RANKL, and phosphorylation of IκBα and JNK was determined by 
Western blot analysis. PLCγ2 expression levels are shown. β-Actin served as loading control in C and D. (E) PLCγ2 and GAB2 were reciprocally 
immunoprecipitated in WT and Plcg2–/– BMMs treated with RANKL and subjected to Western blot analysis using anti-PLCγ2 and anti-GAB2 Abs, 
respectively. TCL, total cell lysate. (F) GAB2 was immunoprecipitated in WT and Plcg2–/– BMMs and subjected to Western blot analysis using 
anti-phosphotyrosine Ab (clone 4G10), anti-RANK, and anti-PLCγ2.
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TNF-α cannot correct the Plcg2–/– OC defect. (A) WT and Plcg2–/– 
BMMs were stimulated with TNF-α (10 ng/ml) with time. Phosphorylated 
JNK, IκBα, and PLCγ2 were examined. β-Actin served as control. (B) 
WT and Plcg2–/– BMMs were cultured for 3 days with RANKL (100 
ng/ml) and M-CSF (10 ng/ml). On day 3 TNF-α was also added to the 
culture media. Cells were fixed and TRAP stained at day 7. Magnifica-
tion, ×200. (C) WT and Plcg2–/– preOCs were stimulated with TNF-α 
or RANKL for the indicated times, and expression levels of NFATc1, 
PLCγ2, and β-actin were determined.
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Western blot analysis and antibodies. BMMs or OCs starved for 6 hours 








































3′;  cathepsin  K  using  5′-ATGTGGGTGTTCAAGTTTCTGC-3′  and 





PLCγ2 in RANKL signaling. PLCγ2 is phosphorylated by RANKL in 
an SFK-dependent manner downstream of Dap12/FcRγ. Activa-
tion of PLCγ2 and PLCγ2 catalytic activity are required for NFATc1 
upregulation (right arm). PLCγ2 can also bind GAB2 and modulate its 
activation and recruitment to the RANK-signaling complex (left arm). 
This interaction might be required for activation of the IκBα/NF-κB and 
JNK/AP1 pathways independent of Dap12/FcRγ.
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